GPD1 modulators(glycerol-3-phosphate dehydrogenase 1 modulators), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseOther Diseases+ [8]

Active Indication

Differentiated Thyroid Gland CarcinomaEpendymomaDepressive Disorder+ [13]

Inactive Indication

Diabetes Mellitus, Type 2Ischemic stroke

Originator Organization

Elcelyx Therapeutics, Inc.

Active Organization

Baylor College of Medicine

University of California, Los Angeles

University of Minnesota

+ [6]

Inactive Organization

Anji Pharmaceuticals, Inc.

Elcelyx Therapeutics, Inc.

National Institute on Drug Abuse

+ [2]

License Organization

Anji Pharmaceuticals (Shanghai) Co., Ltd.

Emory University

Elcelyx Therapeutics, Inc.

+ [3]

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC4H11N5

InChIKeyXZWYZXLIPXDOLR-UHFFFAOYSA-N

CAS Registry657-24-9

417

Clinical Trials associated with Metformin

NCT07226453

/ Not yet recruitingPhase 2IIT

A Target Validation and Efficacy Study of Metformin in Patients With Recurrent or Progressive Posterior Fossa Group A (PFA) Ependymoma

This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.

Start Date28 Feb 2026

Sponsor / Collaborator

The University of California, San Francisco

NCT07007221

/ Not yet recruitingPhase 2IIT

Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV

Depression in HIV occurs commonly and causes poor HIV outcomes with public health implications.
Depression prevalence in HIV-infected persons is estimated at 26% compared to 5% in the general population. Adherence to antiretroviral medication is a life-saving treatment in HIV, but depression can reduce engagement in care and adherence to medication. Depression is also associated with poorer levels of viral suppression and even mortality. Overall, those with depression and HIV are less likely to return to health and remain more likely to transmit the virus. therefore, treatment of HIV is essential to prevention; lower engagement in and adherence to HIV treatment due to depression puts others at risk. This is a 3 part trial, an initial pilot, a placebo controlled pilot, and a full trial.
Part 1. Dose response, Tolerability/Acceptability of Metformin for Depression in people with HIV: To do Initial assessment of metformin for depression in people with HIV we will perform a randomized, double blind, 2-arm, 12 week randomized controlled trial to assess feasibility and acceptability of metformin for depression. We will test two doses of metformin 1000 mg daily versus 1500 mg daily.
Part 2. Preliminary Efficacy Trial of Metformin for Depression in People with HIV: This will be a two-arm, double-blind trial of metformin versus placebo in people with HIV and depression. We will randomize individuals 1:1 to metformin or placebo. Will then collect blood and rectal swabs for preliminary assessments of the mechanism of action for metformin in people with HIV and depression.
Part 3. Full efficacy factorial trial of metformin for depression and comparison/interaction with fluoxetine in people living with HIV: To assess metformin and fluoxetine as efficacious treatments for depression in people with HIV, we will conduct a 4-arm, 12-week, mechanistic, double-blinded, randomized controlled treatment trial (RCT) with an assessment of inflammation and the gut microbiome. Participants (n=400) will be HIV- positive patients on ART with comorbid depression receiving care at one of two Ugandan clinics. In addition, we will use the NIMH Research Domain Criteria (RDoC) of Acute Threat and loss under Negative Valence using biomarkers and self-reported tools.

Start Date01 Jan 2026

Sponsor / Collaborator

University of Minnesota

TCTR20240817009

/ Not yet recruitingPhase 1

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin 50/1000 mg Film-coated Tablets and Reference Product (GALVUS MET (50 MG/1000 MG)) in Healthy Thai Volunteers under Fed Conditions

Start Date06 Feb 2025

Sponsor / Collaborator-

100 Clinical Results associated with Metformin

100 Translational Medicine associated with Metformin

100 Patents (Medical) associated with Metformin

36,931

Literatures (Medical) associated with Metformin

01 Mar 2026·BIOMATERIALS

Senescence-regulating agents remodel mesenchymal stem cell-schwann cell circuitry for diabetic bone regeneration

Article

Author: Liu, Ziyang ; Mao, Jing ; Li, Weiqi ; Xu, Chenci ; Zhuang, Yu ; Sun, Yiting ; Lin, Kaili ; Ge, Linhu ; Wu, Xiangbing ; Wu, Jianyong ; Liu, Jiaqiang ; Lao, An

Bone healing requires Schwann cells (SCs) paracrine factors for mesenchymal stem cell function. Diabetes mellitus (DM) patients are susceptible to developing SCs dysfunction and impairing bone healing. Rare research considered reconstructing mesenchymal stem cell-schwann cell circuitry in diabetic bone regeneration. Here we found that SCs in diabetic microenvironment appeared cellular senescence phenotype with excessive reactive oxygen species (ROS) and mitochondrial dysfunction. To target at senescent SCs, we co-entrapped small interfering RNA that targets P53 (Si-P53) and metformin (MET) in ZIF-8-based nanoparticles (MMZ@Si-P53). Mechanistically, MMZ@Si-P53 affected senescent SCs by promoting mitochondria recovery and serine biosynthesis. In addition, rejuvenation of SCs and recovery of mesenchymal stem cell-schwann cell circuitry inhibited bone marrow mesenchymal stem cells (BMSCs) senescence and improved BMSCs ossification. Subsequently MMZ@Si-P53 loaded into glucose-responsive hydrogel system (MMZ@Si-P53/HAMA-PBA-PVA) for triggering release of nanoparticles in hyperglycemia. MMZ@Si-P53/HAMA-PBA-PVA strongly promoted diabetic bone regeneration in diabetic rat model. Our findings demonstrated the effectiveness of MMZ@Si-P53/HAMA-PBA-PVA system in repairing diabetic bone defects.

01 Feb 2026·Biomaterials advances

Metformin nanoparticles mitigate cerebral ischemia reperfusion injury by improving mitochondrial dysfunction and inhibiting NLRP3 activation

Article

Author: Li, Jiayu ; Guo, Sheng ; Tao, Tao ; Cai, Ting ; Song, Yinfei ; Deng, Lin

BACKGROUND:

Cerebral ischemia reperfusion injury (CIRI) is a serious condition that lacks highly effective treatment methods. After CIRI, microglia in the cortex of mice show high expression of CD44, which offers a potential target for the development of targeted drug-delivery systems to treat ischemic brain injury.

OBJECTIVE:

This study aimed to design a targeted drug-delivery system for ischemic brain injury, and explore the underlying molecular mechanisms on CIRI.

METHODOLOGY:

Hyaluronic acid-PEG-DSPE@metformin (HA@MET) nanoparticles were designed to specifically target the CD44 receptor on microglia. HA@MET was used to intervene in a CIRI mouse model, and then the infarct size and neurological scores were measured. Moreover, experiments on the expression of autophagy-related proteins (Beclin-1, Atg5, Sirt3), the production of reactive oxygen species (ROS), the activation of the NLRP3 inflammasome and the release of associated inflammatory factors (Caspase-1, IL-6, IL-1β) were performed.

RESULTS:

In the CIRI mouse model, HA@MET treatment led to a significant reduction in infarct size and an improvement in neurological scores, indicating a strong therapeutic effect on ischemic brain injury. Mechanistically, HA@MET inhibited the expression of key autophagy proteins Beclin-1 and Atg5, while increasing the expression of Sirt3 protein. This action alleviated excessive mitochondrial autophagy and promoted the clearance of damaged mitochondria. After entering microglia, HA@MET released metformin, which decreased ROS production and inhibited the activation of the NLRP3 inflammasome, resulting in reduced concentrations of inflammatory factors (Caspase-1, IL-6, IL-1β) and alleviating the inflammatory responses associated with CIRI.

CONCLUSIONS:

This study provides new perspectives and potential therapeutic targets for the treatment of ischemic brain injury. HA@MET, as a targeted drug-delivery system, shows promise in treating CIRI through multiple mechanisms, including regulating mitochondrial autophagy and inhibiting inflammation.

01 Feb 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A dual-modality sensor for pre-clicinal imaging of diabetes-associated copper dysregulation in vivo and in urine

Article

Author: Yang, Fangkun ; Jiang, Miaowei ; Chen, Shuqin ; Shang, Jinhui ; Li, Li ; Wang, Kai ; Wei, Hangbiao

Copper ions (Cu²⁺) play a critical role in physiological and pathological processes, including diabetes. However, detecting Cu²⁺ with high sensitivity and specificity in diabetes remains challenging. In this study, we developed a hemicyanine-based copper ion probe (CUP) encapsulated in mPEG-DSPE nanoparticles (CUNP) for dual-modality fluorescence and photoacoustic (PA) imaging of Cu²⁺. CUNP exhibited excellent aqueous solubility, biocompatibility, and a turn-on response to Cu²⁺, with activate signals. In vivo studies in streptozotocin (STZ)-induced diabetic mice revealed elevated hepatic Cu²⁺ levels, which were attenuated by metformin treatment, as confirmed by PA and fluorescence imaging. Urine analysis further revealed elevated Cu²⁺ in diabetic patients. These findings highlight CUNP as a promising tool for non-invasive Cu²⁺ monitoring in diabetes, with potential clinical applications in disease diagnosis and therapeutic evaluation.

130

News (Medical) associated with Metformin

17 Nov 2025

·www.prnewswire.com

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect of Bayer's top selling cancer drug, Stivarga® (regorafenib); such combination could potentially become a life-cycle IP strategy when Stivarga's® main European and U.S. patents expires in August 2028 and July 2032, respectively. New patent applications (US 63/786,370 and US 63/915,832) have been submitted to USPTO. Metformin is typically the first-choice treatment for managing type 2 diabetes and is widely available in generic forms. The combination of Aramchol and Stivarga® is expected to enter phase 1b clinical trials early 2026 in metastatic colorectal cancer (CRC), hepatocellular (HCC) and cholangiocarcinoma patients with a planned expansion cohort including metformin. RAMAT-GAN, Israel, Nov. 17, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today results from its joint research with Virginia Commonwealth University (VCU) evaluating Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. The collaboration is based on breakthrough findings published in Nature Communications linking Aramchol to overcome cancer drug resistance. Previously in May 2025, Galmed announced that Aramchol significantly enhances Bayer's regorafenib effect in GI cancer models to kill GI tumor cells. In that study, Aramchol enhanced both flux and autolysosome formation caused by Regorafenib, activating ATM and AMPK and inactivating mTORC1 and mTORC2 pathways. In addition, Regorafenib and Aramchol interacted to suppress tumor growth in hepatoma models without normal tissue toxicities. Today's announced top line results include new data regarding the synergetic effects of Aramchol and Stivarga® with Metformin. In this latest study, Aramchol demonstrated the mechanism of action of Aramchol's anti-tumor abilities, alone or when combined with the mutli-kinase inhibitor regorafenib and the type 2 diabetes drug, Metformin, suggesting a synergistic effect and potential for fixed dose combination for treatment. Allen Baharaff, President and CEO of Galmed Pharmaceuticals commented: "Stivarga® (regorafenib) is indicated as standard-of-care third line treatment in metastatic colorectal cancer (CRC), as well as advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma. Monoclonal antibodies (MABs), such as atezolizumab & bevacizumab, are the first-line therapy for these patients. However, it is estimated that since around 75% of patients develop resistance or intolerance to MABs and because of their high cost, the cost effectiveness is limited. Stivarga® is Bayer's top selling cancer drug, which generated €458 million (~$500 million) in the first nine months of 2022, up 28% from 2021. The main patent protection for regorafenib is expected to expire in August 2028 in Europe and July 2032 in the U.S., potentially resulting in generic versions of regorafenib becoming available, which could significantly affect Bayer's market share. Based on the top-line results, a fixed dose combination with Aramchol has shown that such combination could potentially become a life-cycle IP strategy for regorafenib to help delay the generic competition." Mr. Baharaff continued "We are looking forward to initiating our Phase 1b study at VCU Massey Comprehensive Cancer Center, which is expected to commence in early 2026. This Phase 1b study will also serve as a proof-of-concept on Aramchol's efficacy in an oncology clinical setting. Positive findings could lay the groundwork for subsequent accelerated clinical development of Aramchol in key three GI cancers, which if successful, could potentially expand Galmed's pipeline and create value for investors and stakeholders." About Galmed Pharmaceuticals Ltd.: We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for the treatment of liver disease and we are currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development. Forward-Looking Statements: Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to the potential synergistic effect of Aramchol, Stivarga® and Metformin as a new fixed-dose combination treatment, how such 3-drug combination could potentially become a life-cycle IP strategy, the expected timing of clinical trials, future clinical development and creating value for investors and stakeholders. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol, or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; the security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel, risks relating to our digital asset management strategy, including the highly volatile nature of the price of cryptocurrencies and other digital assets, the risk that our share price may be highly correlated to the price of the cryptocurrencies and other digital assets that we may hold, risks related to increased competition in the industries in which we do and will operate, risks relating to significant legal, commercial, regulatory and technical uncertainty regarding cryptocurrencies and other digital assets generally, risks relating to the treatment of crypto assets for U.S. and foreign tax purposes and those risks and uncertainties identified in Exhibit 99.2 to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC") on August 25, 2025. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 2, 2025 in greater detail under the heading "Risk Factors." Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties. Logo: SOURCE Galmed Pharmaceuticals Ltd. 21% more press release views with Request a Demo

Phase 1Clinical ResultPatent Expiration

31 Oct 2025

·www.globenewswire.com

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8% Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 28 positively affected by higher sales volume, offset by lower global metformin prices compared to same quarter last year. EBITDA for first three months of 2025 ended at MNOK 89 compared to MNOK 77 YTD 2024, an increase of 16%. The net profit ended at MNOK 18.5 (16.6) for the third quarter of 2025. All time high production volume in the quarter with 1 600MT Metformin produced. The third quarter conference call, which will be held today, 31st of October at 8.30am (CET), will be available via webcast and audio through the following access points: Webcast: https://edge.media-server.com/mmc/p/zojifvb6 Telephone conference (online registration): https://register-conf.media-server.com/register/BI4b6411bcd117427f8df81e59f7b2fd65 The conference call will be held in English. Please find the Q3 report and presentation enclosed. The report and webcast (recorded) will also be made available on www.vistin.com. ***** For further information, please contact: Alexander KarlsenCFO+47 97 05 36 21alexander.karlsen@vistin.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments Vistin Pharma ASA Q3 report 2025 Vistin Pharma_Q3_25_presentation

Financial Statement

28 Oct 2025

·www.globenewswire.com

Former Amazon Care Executive Dr. Sunita Mishra Joins Heald’s Advisory Board to Accelerate Expansion Across Employers and Provider Networks

ALPHARETTA, Ga., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Heald, the human-led, tech-enabled platform redefining Diabetes care, proudly announces that Dr. Sunita Mishra, former Chief Medical Officer of Amazon Health services and CMO for Amazon Care, has joined as an Advisory Board Member. In this role, Dr. Mishra will advise on Heald’s expansion into the employer, provider, and health system markets, bringing her deep expertise in scaling hybrid care models that connect digital technology with real human care. Dr. Mishra brings over two decades of experience at the intersection of clinical practice, consumer innovation, and large-scale healthcare delivery. At Amazon Care, she was instrumental in building and scaling the company’s hybrid primary care model for employers, integrating virtual and in-person care to improve access, convenience, and measurable outcomes. At Amazon Health Services, she focused on using artificial intelligence (AI) and cloud technologies to make healthcare more predictive, personalized, and efficient, a vision that aligns closely with Heald’s mission of data-driven, human-led care. Before that, she served as Chief Executive of Express Care and Vice President of Consumer Innovation at Providence Health & Services, where she led initiatives to make care more patient-centered and digitally accessible. The appointment follows Heald’s growing success on the direct-to-consumer front, where participants have achieved an average 15 lbs weight reduction and a 3% decrease in A1C. Nearly 98% of users have reduced medication usage, with many reducing or fully discontinuing Insulin, Metformin, and GLP-1 drugs. Building on these outcomes, interest from employers, provider organizations, and health systems has grown sharply as they seek scalable solutions that can sustainably lower chronic disease costs and improve overall employee health. As employers and provider groups increasingly turn to Heald for sustainable Diabetes reversal solutions, the company is expanding its reach through an outcomes-based pricing model, an evolution of its Money-Back Guarantee that aligns cost directly with verified health improvements. The model ensures organizations pay only for meaningful outcomes while showcasing Heald’s belief that accountability and value-based care must go hand in hand. This approach builds on the same principles Dr. Mishra helped advance at Amazon Care, where employer-focused hybrid models were designed around accessibility and measurable results. “We’ve proven that reversing Diabetes is possible when you connect real-time metabolic data with personalized expert guidance,” said Sandeep Misra, Co-Founder and Chief Growth Officer at Heald. “Employers and provider networks are realizing this approach can fundamentally change how chronic disease is managed by addressing root causes instead of symptoms. Dr. Mishra built one of the most influential employer-focused care models in the country, and her experience will be instrumental as we extend Heald’s impact across those segments.” Meeting a Growing National Need More than 38 million Americans (14.7% of all U.S. adults) live with Diabetes, and nearly 100 million adults have prediabetes, most without knowing it, according to the CDC. The condition drives over $400 billion in annual healthcare costs, much of which stems from medication dependence, preventable complications, and lost productivity. Employers alone face a projected $90 billion annual burden from Diabetes-related absenteeism and GLP-1 drug spend approaching $12,000 per member per year. Provider organizations are also struggling to balance chronic care demand with staffing and reimbursement pressures. Heald’s approach directly addresses these challenges by connecting continuous glucose monitoring (CGM), smart devices, and wearable data with a dedicated clinical team that includes physicians, nutritionists, fitness coaches, and behavioral experts. This integrated, human-led model bridges the gap between digital convenience and clinical trust, empowering participants to make sustainable changes that improve outcomes and reduce costs for organizations. “Technology alone doesn’t solve healthcare, it’s how we use it to empower people that matters,” said Dr. Sunita Mishra. “What Heald has built is special: a model where human care and digital intelligence work hand-in-hand to drive real, sustainable change. I’m excited to help bring that impact to employers and provider groups ready to make metabolic health a strategic priority.” About Heald Heald is a human-led, tech-enabled health platform that helps people reverse Type 2 Diabetes by addressing the root causes of disease- nutrition, movement, sleep, and stress. Heald connects individuals with smart devices and a multidisciplinary clinical team to provide real-time insights, personalized coaching, and sustainable health transformation. Learn more about Heald’s approach and Money-Back Guarantee at www.iheald.com. Media Contact:Govind KumarPress and Media Relations, Healdgovind@iheald.com www.iheald.com

Executive Change

100 Deals associated with Metformin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Metformin	A10BA02	DB00331

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Differentiated Thyroid Gland Carcinoma	Phase 3	Poland	Medical Research Agency	01 Nov 2022
Ischemic stroke	Phase 3	United States	The Medical University of South Carolina	01 Oct 2008
Diabetes Mellitus, Type 2	Phase 3	United States	National Institute of Diabetes & Digestive & Kidney Diseases	01 May 2004
Ependymoma	Phase 2	United States	The University of California, San Francisco	28 Feb 2026
Depressive Disorder	Phase 2	-	University of Minnesota	01 Jan 2026
HIV Infections	Phase 2	-	University of Minnesota	01 Jan 2026
Monoclonal Gammopathy of Undetermined Significance	Phase 2	United States	Dana-Farber Cancer Institute, Inc.	27 Apr 2021
Plasma Cell Leukemia	Phase 2	United States	Dana-Farber Cancer Institute, Inc.	27 Apr 2021
Smoldering Multiple Myeloma	Phase 2	United States	Dana-Farber Cancer Institute, Inc.	27 Apr 2021
COVID-19	Clinical	United States	University of Minnesota	18 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02946996 (CTgov)	Phase 2	Prostatic Cancer \| Metastatic Prostate Carcinoma \| Adenocarcinoma of prostate	41	Metformin (Metformin Only)	lgjekmutjq(sohyfakvnm) = vgotidvapu zvlfftyppg (pgjzrxcfuf, apfjikzktw - dqhdwgebbf) View more	-	03 Feb 2025
				OPC (OPC Only)	lgjekmutjq(sohyfakvnm) = dxfwnjflwy zvlfftyppg (pgjzrxcfuf, rrjaelgqpq - wafbqijiwc) View more
NCT01107717 (EDICT \| EDICT study, CTgov)	Phase 4	Diabetes Mellitus, Type 2	318	exenatide+pioglitazone+metformin (Triple Therapy)	wgfmkydzka(oxgvdwdvnl) = ovzczqoynk omkujnrbwy (mweutpmkre, 0.1) View more	-	05 Sep 2024
				glargine+metformin+glyburide (Conventional Therapy)	wgfmkydzka(oxgvdwdvnl) = yfjtonogre omkujnrbwy (mweutpmkre, 0.1) View more
NCT04640571 (CTgov)	Phase 4	-	18	Metformin (Metformin)	krrrrydirp(hyxyfxsrmj) = vhccfhdtza jlmchgdwor (aiythacfws, 34.1) View more	-	16 Jul 2024
				placebo+enalaprilat+pravastatin+valacyclovir+CDCA (Placebo)	krrrrydirp(hyxyfxsrmj) = rzbwsngwfe jlmchgdwor (aiythacfws, 24.7) View more
Corporate Publications Manual	Phase 3	Diabetes Mellitus, Type 2	-	恒格列净+二甲双胍 (恒格列净5 mg联合组)	qpgpgaeajp(dqzauuyvee) = lsasnpglfq gzhbkvlqwd (poowymwakr ) View more	Positive	08 Jan 2024
				恒格列净+二甲双胍 (恒格列净10 mg联合组)	qpgpgaeajp(dqzauuyvee) = lmrtnxhpbm gzhbkvlqwd (poowymwakr ) View more
NCT04899349 (EPIK-B4, CTgov)	Phase 2	Advanced breast cancer	2	Fulvestrant+Alpelisib+Dapagliflozin+Metformin XR+Dapagliflozin + metformin XR (Alpelisib + Fulvestrant + Dapagliflozin + Metformin XR)	kvjqiwbwqb = asmfyagmxi vkzcvynucf (utqebvlcjg, wnffhpfetf - avfwltdwhb) View more	-	12 Dec 2023
				Fulvestrant+Alpelisib+Metformin XR (Alpelisib + Fulvestrant + Metformin XR)	hbgejqcudw = mwpdnjcxhl dfmcrztmhq (madzwnofdk, gbihiwnoac - ojzrcqoypw) View more
FDA Manual	Not Applicable	Diabetes Mellitus, Type 2	1,091	Placebo	bbovtinzqx(hpvlfohpcx) = uoccybqszv feucfubkvf (zayrlvuahh ) View more	Positive	03 Nov 2023
				Sitagliptin 100 mg	bbovtinzqx(hpvlfohpcx) = xahebcpxrb feucfubkvf (zayrlvuahh ) View more
JPRN-UMIN000028405 (ESMO 12023 \| ESMO 22023) Manual	Phase 1	Solid tumor	41	Metformin+nivolumab	qemxxbgywj(udlajddrlv) = ofgcmfijug dbvvyokkqe (djuloeagij ) View more	Positive	23 Oct 2023
NCT01968317 (CTgov)	Phase 2	Endometrioid intraepithelial neoplasia \| uterus adenocarcinoma	150	Megestrol acetat+metformin (Megestrol Acetate and Metformin)	ljusxcimcm = lfbatiouhs mtqchmhtvk (sqqozmupdo, nhfmshlyzd - sddkqlrdmz) View more	-	13 Sep 2021
				megestrol acetate (Megestrol Acetate)	ljusxcimcm = rtnsnmffda mtqchmhtvk (sqqozmupdo, kmgvmpixtt - xlwfvulxts) View more
CTRI/2018/07/014865 (P-24, ESMO_GI2021)	Phase 1	Advanced Hepatocellular Carcinoma	40	Sorafenib 800mg	klzxqbomqb(ocpsowiqid) = rlatkdonyf ezyjohstyt (teusrnlzik ) View more	Positive	03 Jul 2021
				Sorafenib 600mg	wzveofnwnv(yrcvfuqfbi) = btulonwndj bemjstbffr (xgwrlfmsdn, 1 - 11)
NCT02496741 (Pubmed \| Cancers (Basel)) Manual	Phase 1/2	IDH1 positive Solid Tumors IDH1 Mutation	12	Metformin+Chloroquine	sjrerhoroi(mepmekjxsx) = ppswnklmmn aelaxpyfjr (iwvcxaiwqj ) View more	Negative	19 May 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Metformin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation